"We enjoy the advantage of having a large amount of clinical data on 2,000 patients. So we analyzed who received which cells and which cells worked best in different conditions. This allowed us to create our selection process through molecular profiling,” explained Medistem (Panama) Founder and CEO Dr. Neil Riordan. Operating what is arguably [...]
(PRWEB) MAY 26, 2016 After several promising treatments in Panama using stem cell technology developed by Medistem Panama Inc. at the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received his first umbilical cord tissue-derived mesenchymal stem cells in the US earlier this year following FDA approval of a second application [...]
Dr. Riordan discusses: How our lab selects uses specialized screening techniques to select only the stem cells that we know will be the most useful for our patients. Only about 1 in 100 cords pass this screening process. How umbilical cord mesenchymal stem cells (MSC) control inflammation, modulate the immune system [...]
